Press releaseNewsfile
OS Therapies
OSTX · NYSE American
$1.26−$0.01 (−0.79%)TodayMarket closed ·
Prev close $1.27
Latest news
- Press releaseGlobe Newswire
Rubenstein Public Relations Named Agency of Record for OS Therapies
- Press releaseNewsfile
OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma
- NewsVandana Singh
OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment
- Press releaseNewsfile
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
- Press releaseNewsfile
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
- Press releaseNewsfile
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
- News
OS Therapies Provided an Update on Global Early Market Access Regulatory Coordination Efforts By UK's MHRA For OST-HER2 For Pulmonary Metastatic Osteosarcoma Under Project Orbis
- Press releaseNewsfile
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
- News
OS Therapies Achieves Incremental FDA Alignment Regarding Its Biologics License Application For OST-HER2 For Prevention Or Delay Of Recurrence In Fully-Resected, Pulmonary Metastatic Osteosarcoma
- NewsVandana Singh
OS Therapies Reports Strong Survival Data for Bone Cancer Treatment
- NewsVandana Singh
OS Therapies Says New Bone Cancer Data Strengthens Case For Regulatory Filings
- News
Earnings Scheduled For May 18, 2026
- Press releaseBusiness Wire
OS Therapies Investor News: Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX
- Press releaseBusiness Wire
Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releasePRNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of OS Therapies Incorporated (NYSE American: OSTX)
- News
OS Therapies Targets January 2026 BLA Filing for OST-HER2, Expects PRV Revenue in 2026
- Press releaseNewsfile
OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
- NewsAvi Kapoor
Why Quantum Computing Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket
- Press releaseNewsfile
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma
- News
Earnings Outlook For OS Therapies
- Press releaseNewsfile
OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
- Press releaseNewsfile
OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
- Press releasePRNewswire
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
- Press releaseNewsfile
OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer
- Press releaseNewsfile
OS Therapies Provides Clinical & Global Regulatory Updates
- Press releaseBusiness Wire
OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
- Press releaseBusiness Wire
OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference
- Press releasePRNewswire
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
- Press releaseBusiness Wire
OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
- Press releaseBusiness Wire
OS Therapies Announces Warrant Exercise Inducement & Exchange Offer
- Press releasePRNewswire
OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
- Press releaseBusiness Wire
OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma
- Press releaseBusiness Wire
OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update
- Press releaseBusiness Wire
OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma
- Press releaseBusiness Wire
OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040
- Press releaseBusiness Wire
Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies
- Press releaseBusiness Wire
OS Therapies FDA Meeting Request Granted
- Press releasePRNewswire
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz
- Press releaseBusiness Wire
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
- Press releaseNewsfile
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
- Press releaseBusiness Wire
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
OS Therapies Launches Subsidiary to Advance Tunable Antibody Drug Conjugates, Plans Stock Dividends for Shareholders
- Press releaseBusiness Wire
OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseACCESS Newswire
RedChip Launches RedChat: Revolutionary AI Chatbot for Small-Cap Stock Analysis
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.